Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances

2 days ago 5

Attiya Zainib

Mon, February 2, 2026 astatine 8:33 AM CST 3 min read

Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Apis Flagship Fund delivered beardown show successful the 4th fourth of 2025, with the Fund up 10.0% nett for the 4th and gaining 55.1% for the afloat year, importantly outperforming the MSCI ACWI planetary benchmark by astir 7.0% successful Q4 and 33.0% for the year. Long positions drove the bulk of gains arsenic they generated 11.9% gross contribution, portion shorts added a further 0.8% gross, with the portfolio positioned astir 68% nett agelong arsenic of December. Performance was broad-based, arsenic Technology and Healthcare led quarterly returns, and beardown contributions besides came from basal materials, portion small-capitalization stocks narrowed their accepted underperformance comparative to ample caps. Looking ahead, the steadfast highlighted its continued accent connected bottom-up banal selection, structural exposures to niche opportunities crossed healthcare, semiconductors, and industrials, and the persistent attractiveness of non-U.S. markets arsenic cardinal drivers for aboriginal imaginable returns. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Apis Capital Advisors highlighted stocks similar Celcuity Inc (NASDAQ:CELC). Celcuity Inc (NASDAQ:CELC) is simply a clinical-stage biotechnology institution processing precision oncology therapies utilizing its CELsignia level to place crab patients astir apt to payment from targeted treatments. The one-month instrumentality of Celcuity Inc (NASDAQ:CELC) was 5.41% portion its shares traded betwixt $7.58 and $120.32 implicit the past 52 weeks. On January 30, 2026, Celcuity Inc (NASDAQ:CELC) banal closed astatine astir $109.42 per share, with a marketplace capitalization of astir $5.06 billion.

Apis Capital Advisors’ Apis Flagship Fund stated the pursuing regarding Celcuity Inc (NASDAQ:CELC) successful its Q4 2025 capitalist letter:

"Stock enactment was the superior operator of show successful the 4th quarter, with agelong positions generating returns much than 3 times benchmark levels, portion abbreviated positions besides contributed modestly. All regions and sectors were affirmative – North America and Asia accounted for the bulk of gains, portion Europe contributed little but mostly successful enactment with its determination weighting. From a assemblage perspective, Technology and Healthcare led quarterly performance. The apical contributor successful Q4 was Celcuity Inc (NASDAQ:CELC), a healthcare sanction highlighted successful our past quarterly letter, which added 3.8% during the 4th and 4.4% for the afloat year. "